Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Abeona Therapeutics Inc’s stock clocked out at $6.28, up 0.64% from its previous closing price of $6.24. In other words, the price has increased by $0.64 from its previous closing price. On the day, 1.01 million shares were traded.
Ratios:
To gain a deeper understanding of ABEO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.58 whereas as Long-Term Debt/Eq ratio is at 0.37.
On March 05, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $16.
On July 03, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $15.H.C. Wainwright initiated its Buy rating on July 03, 2024, with a $15 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 27 ’25 when Alvino Mark sold 2,000 shares for $6.38 per share. The transaction valued at 12,760 led to the insider holds 90,435 shares of the business.
Alvino Mark bought 2,000 shares of ABEO for $12,762 on May 27 ’25. On May 16 ’25, another insider, Alvino Mark, who serves as the Director of the company, sold 8,000 shares for $5.68 each. As a result, the insider received 45,440 and left with 92,435 shares of the company.
Stock Price History:
Over the past 52 weeks, ABEO has reached a high of $7.32, while it has fallen to a 52-week low of $3.93. The 50-Day Moving Average of the stock is 15.64%, while the 200-Day Moving Average is calculated to be 10.19%.
Shares Statistics:
A total of 48.95M shares are outstanding, with a floating share count of 45.21M. Insiders hold about 11.62% of the company’s shares, while institutions hold 59.05% stake in the company.
Earnings Estimates
Its stock is currently analyzed by 4.0 different market analysts. The consensus estimate for the next quarter is $0.28, with high estimates of $1.98 and low estimates of -$0.33.
Analysts are recommending an EPS of between $1.35 and -$1.2 for the fiscal current year, implying an average EPS of -$0.46. EPS for the following year is -$0.21, with 4.0 analysts recommending between $0.04 and -$0.35.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $6.61M. There is a high estimate of $10.87M for the next quarter, whereas the lowest estimate is $2.33M.
Based on 7 analysts’ estimates, the company’s revenue will be $106.05M in the next fiscal year. The high estimate is $130.35M and the low estimate is $64.75M.
